Amgen Sues Colorado After Drug's 'Unaffordable' Rating
IP Law 360
MARCH 25, 2024
Amgen has sued the Colorado Prescription Drug Affordability Review Board in federal court after receiving a determination that one of its arthritis drugs is "unaffordable," saying the board is using unconstitutionally "unguided discretion" to impose arbitrary price controls on patent-protected drugs.
Let's personalize your content